Modeling pediatric AML FLT3 mutations using CRISPR/Cas12a- mediated gene editing

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• CRISPR-Cas systems offer precise and accessible genetic engineering tools.
• Acute myeloid leukemia (AML) often involves mutations in the FLT3 gene.
• Understanding FLT3 mutations is crucial for AML treatment strategies.

Purpose of the Study:

• To apply CRISPR-directed mutagenesis (CDM) to reconstruct complex FLT3 gene mutations from AML patients.
• To investigate how these reconstructed mutations affect cellular transformation in Ba/F3 cells.
• To determine the impact of patient-specific FLT3 mutations on drug sensitivity in AML.

Main Methods:

• Utilized CRISPR-directed mutagenesis (CDM) to create expression vectors.
• Designed donor DNA fragments to recapitulate simple and complex FLT3 mutations, including insertions and point mutations.
• Introduced patient-derived FLT3 mutations into Ba/F3 cells for functional analysis.

Main Results:

• CDM successfully generated FLT3 expression plasmids with patient-specific single and multiple mutations.
• Reconstructed FLT3 mutations recapitulated cellular transformation properties similar to FLT3 internal tandem duplications (ITDs).
• The specific combination of FLT3 mutations modulated cellular sensitivity and resistance to established AML drugs.

Conclusions:

• CRISPR-directed mutagenesis is a versatile tool for modeling complex genetic alterations in AML.
• Patient-specific FLT3 mutations significantly influence leukemic cell transformation and drug response.
• This approach provides a platform for studying genotype-phenotype relationships in AML and developing targeted therapies.